Pharmacogenomics Services Market Expected to Exceed 10% CAGR by 2033, Driven by Personalized Medicine and Declining Sequencing Costs
The pharmacogenomics services market is experiencing rapid expansion, projected to grow at a compound annual growth rate (CAGR) exceeding 10% between 2026 and 2033. This growth is primarily fueled by the decreasing cost of genomic sequencing, which makes broader clinical adoption more feasible. The market is also benefiting from a surge in personalized medicine initiatives and increasing regulatory support for companion diagnostics. Key industry players, including established diagnostics giants like Abbott, Roche, Thermo Fisher, Illumina, and QIAGEN, are supplying high-throughput sequencing platforms and diagnostic assays. Clinical delivery is dominated by Quest Diagnostics and LabCorp, while companies such as Myriad Genetics, Exact Sciences, and 23andMe are expanding consumer access to genetic insights for drug metabolism. New entrants like Dynamic DNA Laboratories and Admera Health are focusing on rapid, targeted panels, contributing to the market's diversification and accessibility. The integration of p...
